Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
Immunobiology
|
December 14, 2011
Induction of an anti-inflammatory human monocyte subtype is a unique property of glucocorticoids, but can be modified by IL-6 and IL-10
Athanasios Tsianakas, Georg Varga, Katarzyna Barczyk, et al.
Dermatology and Therapy
|
February 1, 2024
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Kristian Reich, Luca Bianchi, Abdallah Khemis, et al.
Journal of the American Academy of Dermatology
|
September 1, 2025
Efficacy and Safety of Ruxolitinib Cream for the Treatment of Moderate to Severe Chronic Hand Eczema: Results From a 16-Week, Multicenter, Randomized, Double-Blind Study
Matthew Zirwas, Joseph F Fowler, Athanasios Tsianakas, et al.
The Journal of Allergy and Clinical Immunology
|
November 12, 2018
Efficacy and safety of the histamine H<sub>4</sub> receptor antagonist ZPL-3893787 in patients with atopic dermatitis
Thomas Werfel, Gary Layton, Michael Yeadon, et al.
European Journal of Dermatology : EJD
|
April 6, 2013
Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers
Saskia Eichner, Sybille Thoma-Uszynski, Ilka Herrgott, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
November 10, 2010
Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician
Ralf Gutzmer, Jürgen C Becker, Alexander Enk, et al.
Dermatology and Therapy
|
July 2, 2024
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations
Melinda J Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
Acta Dermato-Venereologica
|
January 18, 2019
Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)
Athanasios Tsianakas, Claudia Zeidler, Claudia Riepe, et al.
Acta Dermato-Venereologica
|
November 20, 2024
Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study
Lina Renkhold, Manuel P Pereira, Karin Loser, et al.
The British Journal of Dermatology
|
June 28, 2025
Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)
Melinda Gooderham, Tiago Torres, Shinichi Imafuku, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
Immunobiology
|
December 14, 2011
Induction of an anti-inflammatory human monocyte subtype is a unique property of glucocorticoids, but can be modified by IL-6 and IL-10
Athanasios Tsianakas, Georg Varga, Katarzyna Barczyk, et al.
Dermatology and Therapy
|
February 1, 2024
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Kristian Reich, Luca Bianchi, Abdallah Khemis, et al.
Journal of the American Academy of Dermatology
|
September 1, 2025
Efficacy and Safety of Ruxolitinib Cream for the Treatment of Moderate to Severe Chronic Hand Eczema: Results From a 16-Week, Multicenter, Randomized, Double-Blind Study
Matthew Zirwas, Joseph F Fowler, Athanasios Tsianakas, et al.
The Journal of Allergy and Clinical Immunology
|
November 12, 2018
Efficacy and safety of the histamine H<sub>4</sub> receptor antagonist ZPL-3893787 in patients with atopic dermatitis
Thomas Werfel, Gary Layton, Michael Yeadon, et al.
European Journal of Dermatology : EJD
|
April 6, 2013
Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers
Saskia Eichner, Sybille Thoma-Uszynski, Ilka Herrgott, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
November 10, 2010
Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician
Ralf Gutzmer, Jürgen C Becker, Alexander Enk, et al.
Dermatology and Therapy
|
July 2, 2024
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations
Melinda J Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
Acta Dermato-Venereologica
|
January 18, 2019
Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)
Athanasios Tsianakas, Claudia Zeidler, Claudia Riepe, et al.
Acta Dermato-Venereologica
|
November 20, 2024
Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study
Lina Renkhold, Manuel P Pereira, Karin Loser, et al.
The British Journal of Dermatology
|
June 28, 2025
Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)
Melinda Gooderham, Tiago Torres, Shinichi Imafuku, et al.
Page
of 7